Back to News
Market Impact: 0.3
Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline
Source: Nasdaq
Corporate EarningsHealthcare & BiotechArtificial IntelligenceCompany Fundamentals
Recursion Pharmaceuticals reported a narrower net loss for the quarter ended September 30, 2026, and positive REC-4881 data in familial adenomatous polyposis. The provided article excerpt gives no loss figure or further details on the data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
RXRX0.45
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell-Lumentum Deal Puts Optical Networking at the Center of the AI Boom
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AI Inference Startup Fal Raises Capital at $16 Billion Valuation